benazepril 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
angiotensin-converting enzyme inhibitors	299	86541-75-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: benazepril cibacen benazepril hydrochloride benazepril HCl	prodrug of benazeprilat inhibit angiotensin-converting enzyme (ACE) and results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decreased aldosterone secretion Molecular weight: 424.50 Formula: C24H28N2O5 CLOGP: 1.82 LIPINSKI: 0 HAC: 7 HDO: 2 TPSA: 95.94 ALOGS: -4.61 ROTB: 10 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

benazepril
cibacen
benazepril hydrochloride
benazepril HCl

prodrug of benazeprilat inhibit angiotensin-converting enzyme (ACE) and results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decreased aldosterone secretion

Molecular weight: 424.50
Formula: C24H28N2O5
CLOGP: 1.82
LIPINSKI: 0
HAC: 7
HDO: 2
TPSA: 95.94
ALOGS: -4.61
ROTB: 10

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
7.50	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	78 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	3.13 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	18 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
June 25, 1991	FDA	US PHARMS HOLDINGS I

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Angioedema	142.96	12.65	111	16890	37565	50550558
Cerebrovascular accident	117.99	12.65	152	16849	94528	50493595
Coronary artery disease	107.17	12.65	85	16916	29641	50558482
Myocardial infarction	104.81	12.65	139	16862	88888	50499235
Cardiac failure congestive	95.11	12.65	129	16872	84253	50503870
Off label use	55.36	12.65	47	16954	474379	50113744
Drug ineffective	50.68	12.65	127	16874	819206	49768917
Maternal exposure during pregnancy	42.10	12.65	3	16998	159775	50428348
Transient ischaemic attack	40.50	12.65	52	16949	32158	50555965
Chest pain	39.59	12.65	140	16861	176742	50411381
Contraindicated product administered	38.67	12.65	3	16998	148955	50439168
Blood pressure inadequately controlled	36.31	12.65	21	16980	4359	50583764
Swollen tongue	34.09	12.65	45	16956	28585	50559538
Drug intolerance	33.29	12.65	16	16985	219088	50369035
Dizziness	33.03	12.65	214	16787	346155	50241968
Mitral valve incompetence	31.62	12.65	34	16967	17437	50570686
Vasodilatation	30.40	12.65	15	16986	2264	50585859
Treatment failure	30.17	12.65	5	16996	137632	50450491
Oropharyngeal swelling	30.02	12.65	11	16990	795	50587328
Carotid artery stenosis	29.74	12.65	19	16982	4712	50583411
Infusion related reaction	29.63	12.65	10	16991	169547	50418576
Product complaint	29.44	12.65	27	16974	11439	50576684
Renal failure	28.82	12.65	90	16911	106543	50481580
Oedema peripheral	28.69	12.65	117	16884	157844	50430279
Arteriosclerosis	28.58	12.65	24	16977	9053	50579070
Angina unstable	28.14	12.65	21	16980	6685	50581438
Systemic lupus erythematosus	26.93	12.65	7	16994	140615	50447508
Kounis syndrome	26	12.65	11	16990	1164	50586959
Cardiac disorder	24.13	12.65	48	16953	42931	50545192
Emotional distress	23.82	12.65	38	16963	28625	50559498
Cardiovascular disorder	23.75	12.65	23	16978	10431	50577692
Glossodynia	23.61	12.65	5	16996	115564	50472559
Injury	23.22	12.65	51	16950	48874	50539249
Exposure during pregnancy	23.21	12.65	6	16995	121009	50467114
Completed suicide	22.61	12.65	96	16905	131793	50456330
Tricuspid valve incompetence	21.62	12.65	24	16977	12746	50575377
Renal injury	21.57	12.65	20	16981	8591	50579532
Reaction to excipient	19.63	12.65	9	16992	1153	50586970
Depression	19.41	12.65	108	16893	165315	50422808
Wound	18.89	12.65	6	16995	105788	50482335
Rhabdomyolysis	18.88	12.65	41	16960	38986	50549137
Blood pressure increased	18.43	12.65	91	16910	133041	50455082
Gastrooesophageal reflux disease	18.37	12.65	62	16939	76366	50511757
Hyperdynamic left ventricle	18.01	12.65	5	16996	146	50587977
Arteriosclerosis coronary artery	17.72	12.65	17	16984	7619	50580504
Swelling face	17.67	12.65	48	16953	52547	50535576
Fear	17.52	12.65	23	16978	14526	50573597
Gastrointestinal haemorrhage	17.20	12.65	59	16942	73262	50514861
Palpitations	17.14	12.65	70	16931	94436	50493687
Vasoplegia syndrome	16.87	12.65	8	16993	1106	50587017
Dehydration	16.87	12.65	98	16903	152351	50435772
Keratoacanthoma	16.56	12.65	6	16995	420	50587703
Coronary artery occlusion	16.10	12.65	16	16985	7487	50580636
Tendon rupture	14.89	12.65	15	16986	7129	50580994
Rhinitis allergic	14.80	12.65	15	16986	7185	50580938
Blood glucose increased	14.69	12.65	55	16946	71269	50516854
Peripheral vascular disorder	14.28	12.65	13	16988	5454	50582669
Blood urea increased	14.04	12.65	27	16974	23558	50564565
Pyrexia	13.98	12.65	73	16928	380130	50207993
Joint swelling	13.55	12.65	40	16961	245246	50342877
Hiatus hernia	13.46	12.65	23	16978	18321	50569802
C-reactive protein increased	13.32	12.65	3	16998	66471	50521652
Pericarditis	13.12	12.65	5	16996	78684	50509439
Cardiomegaly	13.05	12.65	21	16980	15924	50572199
Laryngeal pain	13.01	12.65	11	16990	4188	50583935
Hyperlipidaemia	12.93	12.65	22	16979	17468	50570655
Haemorrhoids	12.83	12.65	23	16978	19030	50569093
Muscle spasms	12.79	12.65	79	16922	125474	50462649

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Angioedema	193.06	13.42	141	13483	31774	29529129
Myocardial infarction	122.93	13.42	198	13426	110098	29450805
Coronary artery disease	101.35	13.42	113	13511	44077	29516826
Cardiac failure congestive	69.98	13.42	126	13498	76455	29484448
Cerebrovascular accident	67.06	13.42	124	13500	76787	29484116
Off label use	47.99	13.42	41	13583	300759	29260144
Injury	32.58	13.42	42	13582	19004	29541899
Swollen tongue	29.16	13.42	32	13592	12234	29548669
Chest pain	26.55	13.42	112	13512	111861	29449042
Product complaint	26.28	13.42	21	13603	5384	29555519
Emotional distress	25.92	13.42	32	13592	13863	29547040
Blood glucose increased	24.44	13.42	71	13553	58913	29501990
Nodular rash	22.70	13.42	6	13618	104	29560799
Lymphomatoid papulosis	19.52	13.42	6	13618	182	29560721
Blood pressure inadequately controlled	17.79	13.42	12	13612	2374	29558529
Neutropenia	17.45	13.42	21	13603	131690	29429213
Blood gases abnormal	17.09	13.42	6	13618	278	29560625
Carotid artery stenosis	16.85	13.42	15	13609	4454	29556449
Asthenia	16.83	13.42	162	13462	215088	29345815
Shock	16.74	13.42	33	13591	21371	29539532
Pancreatitis	16.72	13.42	44	13580	34470	29526433
Depression	16.30	13.42	80	13544	85067	29475836
Lip swelling	16.16	13.42	24	13600	12386	29548517
Hyperlipidaemia	15.90	13.42	24	13600	12566	29548337
Angina unstable	15.59	13.42	22	13602	10843	29550060
Acute myocardial infarction	15.20	13.42	53	13571	48385	29512518
Dizziness	14.93	13.42	143	13481	189541	29371362
Product use in unapproved indication	14.85	13.42	11	13613	86864	29474039
Fear	14.77	13.42	20	13604	9484	29551419
Toxicity to various agents	14.54	13.42	37	13587	173624	29387279
Type 2 diabetes mellitus	14.54	13.42	24	13600	13557	29547346
Nephrogenic systemic fibrosis	14.41	13.42	13	13611	3929	29556974
Drug interaction	14.35	13.42	45	13579	197340	29363563
Cardiovascular disorder	14.19	13.42	19	13605	8916	29551987
Anxiety	14.12	13.42	77	13547	85288	29475615
General physical health deterioration	14.05	13.42	16	13608	102841	29458062
Lacunar infarction	13.81	13.42	11	13613	2808	29558095
Transient ischaemic attack	13.73	13.42	32	13592	23238	29537665
Pharyngeal oedema	13.70	13.42	15	13609	5719	29555184

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Angioedema	286.25	12.10	214	23887	61607	64413024
Myocardial infarction	234.74	12.10	299	23802	165522	64309109
Coronary artery disease	223.02	12.10	183	23918	60250	64414381
Cerebrovascular accident	178.86	12.10	238	23863	137345	64337286
Cardiac failure congestive	142.91	12.10	208	23893	130372	64344259
Off label use	89.44	12.10	64	24037	632742	63841889
Transient ischaemic attack	50.61	12.10	72	24029	44110	64430521
Chest pain	49.78	12.10	197	23904	235783	64238848
Emotional distress	47.72	12.10	63	24038	35975	64438656
Angina unstable	47.11	12.10	42	24059	15425	64459206
Injury	45.63	12.10	78	24023	55914	64418717
Carotid artery stenosis	42.39	12.10	30	24071	7911	64466720
Swollen tongue	41.57	12.10	58	24043	34896	64439735
Product complaint	41.54	12.10	35	24066	11919	64462712
Cardiac disorder	40.63	12.10	74	24027	55742	64418889
Blood pressure inadequately controlled	37.52	12.10	24	24077	5360	64469271
Cardiovascular disorder	36.67	12.10	37	24064	15844	64458787
Arteriosclerosis	33.07	12.10	35	24066	15842	64458789
Drug abuse	33.05	12.10	5	24096	132369	64342262
Drug intolerance	32.15	12.10	15	24086	187977	64286654
Renal failure	31.54	12.10	143	23958	181545	64293086
Mitral valve incompetence	31.30	12.10	43	24058	25495	64449136
Drug ineffective	30.93	12.10	186	23915	840061	63634570
Depression	30.88	12.10	143	23958	183148	64291483
Contraindicated product administered	29.53	12.10	3	24098	107826	64366805
Neutropenia	29.07	12.10	28	24073	239596	64235035
Hyperlipidaemia	28.63	12.10	39	24062	22937	64451694
Acute myocardial infarction	28.32	12.10	73	24028	69645	64404986
Fear	27.85	12.10	36	24065	20135	64454496
Dizziness	26.96	12.10	262	23839	429901	64044730
Peripheral vascular disorder	26.77	12.10	22	24079	7239	64467392
Maternal exposure during pregnancy	25.41	12.10	3	24098	95881	64378750
Pyrexia	25.37	12.10	115	23986	558529	63916102
Arteriosclerosis coronary artery	25.10	12.10	30	24071	15499	64459132
Vasodilatation	24.95	12.10	15	24086	3003	64471628
Blood pressure increased	24.33	12.10	128	23973	172424	64302207
Infusion related reaction	23.97	12.10	16	24085	164451	64310180
Treatment failure	23.87	12.10	7	24094	116809	64357822
Renal injury	23.62	12.10	29	24072	15400	64459231
Product use in unapproved indication	23.38	12.10	19	24082	176599	64298032
Tricuspid valve incompetence	22.93	12.10	30	24071	16973	64457658
Anxiety	22.47	12.10	141	23960	202508	64272123
Blood glucose increased	22.37	12.10	84	24017	97989	64376642
Shock	22.09	12.10	46	24055	38194	64436437
Lacunar infarction	20.89	12.10	17	24084	5515	64469116
Ventricular hypertrophy	20.45	12.10	18	24083	6498	64468133
Kounis syndrome	19.89	12.10	13	24088	3012	64471619
Exposure during pregnancy	19.23	12.10	3	24098	77672	64396959
Rheumatoid arthritis	19.00	12.10	20	24081	164274	64310357
C-reactive protein increased	18.82	12.10	6	24095	94903	64379728
Palpitations	18.68	12.10	83	24018	104405	64370226
Drug interaction	18.60	12.10	71	24030	362012	64112619
Oropharyngeal swelling	18.51	12.10	9	24092	1182	64473449
Laryngeal pain	18.48	12.10	16	24085	5652	64468979
Pancytopenia	18.25	12.10	16	24085	143293	64331338
Anhedonia	18.20	12.10	24	24077	13682	64460949
Gastrooesophageal reflux disease	17.96	12.10	70	24031	83073	64391558
Coronary artery occlusion	17.95	12.10	24	24077	13867	64460764
Oedema peripheral	17.80	12.10	137	23964	210180	64264451
Nodular rash	17.61	12.10	6	24095	314	64474317
Lymphomatoid papulosis	17.51	12.10	6	24095	320	64474311
Reaction to excipient	17.11	12.10	9	24092	1394	64473237
Cardiomegaly	16.72	12.10	31	24070	23653	64450978
Asthenia	16.66	12.10	238	23863	427806	64046825
Unevaluable event	16.65	12.10	49	24052	50440	64424191
Pancreatitis	16.12	12.10	54	24047	59553	64415078
Myocardial ischaemia	15.88	12.10	30	24071	23221	64451410
Completed suicide	15.68	12.10	140	23961	224274	64250357
Febrile neutropenia	15.55	12.10	29	24072	187628	64287003
Hypertensive heart disease	15.02	12.10	12	24089	3792	64470839
Gastrointestinal haemorrhage	14.61	12.10	92	24009	132220	64342411
Swelling face	14.60	12.10	52	24049	59114	64415517
Hyperdynamic left ventricle	14.25	12.10	5	24096	286	64474345
Atrial fibrillation	14.22	12.10	111	23990	170978	64303653
Type 2 diabetes mellitus	14.20	12.10	36	24065	33984	64440647
Ischaemic cardiomyopathy	14.11	12.10	15	24086	6823	64467808
Electrocardiogram QT prolonged	14.11	12.10	6	24095	79442	64395189
Gastritis	13.71	12.10	41	24060	42577	64432054
Systemic lupus erythematosus	13.56	12.10	6	24095	77606	64397025
Joint swelling	13.26	12.10	39	24062	215343	64259288
Wound	13.22	12.10	6	24095	76471	64398160
Urinary tract stoma complication	13.15	12.10	3	24098	34	64474597
Tendon rupture	13.00	12.10	18	24083	10749	64463882
Neck injury	12.94	12.10	9	24092	2309	64472322
Blood urea increased	12.83	12.10	41	24060	44112	64430519
Thrombocytopenia	12.74	12.10	42	24059	223759	64250872
Therapeutic product effect incomplete	12.64	12.10	12	24089	103470	64371161
General physical health deterioration	12.60	12.10	37	24064	204388	64270243
Lip swelling	12.53	12.10	33	24068	31874	64442757
Pericarditis	12.31	12.10	4	24097	62512	64412119
Rhabdomyolysis	12.21	12.10	67	24034	91659	64382972
Coronary artery surgery	12.16	12.10	4	24097	188	64474443

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C09AA07	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ACE INHIBITORS, PLAIN ACE inhibitors, plain
ATC	C09BA07	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ACE INHIBITORS, COMBINATIONS ACE inhibitors and diuretics
FDA MoA	N0000000181	Angiotensin-converting Enzyme Inhibitors
FDA EPC	N0000175562	Angiotensin Converting Enzyme Inhibitor
CHEBI has role	CHEBI:35457	ACE inhibitor
CHEBI has role	CHEBI:50266	Prodrugs
MeSH PA	D000806	Angiotensin-Converting Enzyme Inhibitors
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D011480	Protease Inhibitors
FDA PE	N0000178477	Decreased Blood Pressure

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypertensive disorder	indication	38341003	DOID:10763
Chronic heart failure	off-label use	48447003
Atrial fibrillation	off-label use	49436004	DOID:0060224
Diabetic renal disease	off-label use	127013003
Acute scleroderma renal crisis	off-label use	236503001
Diastolic heart failure	off-label use	418304008	DOID:9775
Hypertension due to Scleroderma	off-label use
Nondiabetic Proteinuric Nephropathy	off-label use
Anuria	contraindication	2472002	DOID:2983
Hypercholesterolemia	contraindication	13644009
Hyperkalemia	contraindication	14140009
Jaundice	contraindication	18165001
Secondary angle-closure glaucoma	contraindication	21571006
Hypovolemia	contraindication	28560003
Dehydration	contraindication	34095006
Hyperuricemia	contraindication	35885006	DOID:1920
Angioedema	contraindication	41291007	DOID:1558
Hypokalemia	contraindication	43339004
Low blood pressure	contraindication	45007003
Systemic lupus erythematosus	contraindication	55464009	DOID:9074
Sympathectomy	contraindication	57071006
Hepatic failure	contraindication	59927004
Hypercalcemia	contraindication	66931009	DOID:12678
Hyperparathyroidism	contraindication	66999008	DOID:13543
Hypochloremic alkalosis	contraindication	70134007
Hepatic coma	contraindication	72836002	DOID:12550
Diabetes mellitus	contraindication	73211009	DOID:9351
Chronic idiopathic constipation	contraindication	82934008
Hereditary angioneurotic edema	contraindication	82966003	DOID:14735
Hyponatremia	contraindication	89627008
Gout	contraindication	90560007	DOID:13189
Kidney disease	contraindication	90708001	DOID:557
Disorder of connective tissue	contraindication	105969002	DOID:65
Liver function tests abnormal	contraindication	166603001
Hypomagnesemia	contraindication	190855004
Acute pancreatitis	contraindication	197456007	DOID:2913
Disease of liver	contraindication	235856003	DOID:409
Neonatal hyperbilirubinemia	contraindication	281610001
Pregnancy, function	contraindication	289908002
Renal artery stenosis	contraindication	302233006
Neutropenic disorder	contraindication	303011007	DOID:1227
Bone marrow depression	contraindication	307762000
Azotemia	contraindication	445009001
Intestinal Angioedema	contraindication
Head and Neck Angioedema	contraindication
Hemodialysis with High-Flux Membrane	contraindication
Severe Aortic Valve Stenosis	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

Product	Applicant	Ingredients
Cardalis	Ceva Sante Animale	2

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.9	acidic
pKa2	5.34	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Angiotensin-converting enzyme	Enzyme	P12821	ACE_HUMAN	INHIBITOR	IC50	6.51	WOMBAT-PK	CHEMBL
Angiotensin-converting enzyme	Enzyme		ACE_RABIT		IC50	8.70	CHEMBL
Angiotensin-converting enzyme	Enzyme		ACE_RAT		IC50	8.77	CHEMBL

External reference:

ID	Source
4020817	VUID
N0000148336	NUI
D00620	KEGG_DRUG
86541-74-4	SECONDARY_CAS_RN
1546196	RXNORM
C0053091	UMLSCUI
CHEBI:3011	CHEBI
CHEBI:88200	CHEBI
CHEMBL838	ChEMBL_ID
CHEMBL1694	ChEMBL_ID
DB00542	DRUGBANK_ID
C044946	MESH_SUPPLEMENTAL_RECORD_UI
5362124	PUBCHEM_CID
6374	IUPHAR_LIGAND_ID
C052133	MESH_SUPPLEMENTAL_RECORD_UI
6375	IUPHAR_LIGAND_ID
6129	INN_ID
86541-78-8	SECONDARY_CAS_RN
UDM7Q7QWP8	UNII
5463984	PUBCHEM_CID
DB14125	DRUGBANK_ID
1267	MMSL
4251	MMSL
48720	MMSL
d00730	MMSL
003597	NDDF
003598	NDDF
4020025	VANDF
4020817	VANDF
C0105523	UMLSCUI
CHEMBL1192519	ChEMBL_ID
6128	INN_ID
108572003	SNOMEDCT_US
108573008	SNOMEDCT_US
372511001	SNOMEDCT_US
JRM708L703	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Lotrel	HUMAN PRESCRIPTION DRUG LABEL	2	0078-0364	CAPSULE	20 mg	ORAL	NDA	31 sections
Lotrel	HUMAN PRESCRIPTION DRUG LABEL	2	0078-0364	CAPSULE	20 mg	ORAL	NDA	31 sections
Lotrel	HUMAN PRESCRIPTION DRUG LABEL	2	0078-0379	CAPSULE	40 mg	ORAL	NDA	31 sections
Lotrel	HUMAN PRESCRIPTION DRUG LABEL	2	0078-0379	CAPSULE	40 mg	ORAL	NDA	31 sections
Lotrel	HUMAN PRESCRIPTION DRUG LABEL	2	0078-0405	CAPSULE	10 mg	ORAL	NDA	31 sections
Lotrel	HUMAN PRESCRIPTION DRUG LABEL	2	0078-0405	CAPSULE	10 mg	ORAL	NDA	31 sections
Lotrel	HUMAN PRESCRIPTION DRUG LABEL	2	0078-0406	CAPSULE	20 mg	ORAL	NDA	31 sections
Lotrel	HUMAN PRESCRIPTION DRUG LABEL	2	0078-0406	CAPSULE	20 mg	ORAL	NDA	31 sections
Benazepril Hydrochloride and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0185-0211	TABLET, FILM COATED	20 mg	ORAL	ANDA	22 sections
Benazepril Hydrochloride and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0185-0211	TABLET, FILM COATED	20 mg	ORAL	ANDA	22 sections
Benazepril Hydrochloride and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0185-0236	TABLET, FILM COATED	5 mg	ORAL	ANDA	22 sections
Benazepril Hydrochloride and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0185-0236	TABLET, FILM COATED	5 mg	ORAL	ANDA	22 sections
Benazepril Hydrochloride and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0185-0277	TABLET, FILM COATED	20 mg	ORAL	ANDA	22 sections
Benazepril Hydrochloride and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0185-0277	TABLET, FILM COATED	20 mg	ORAL	ANDA	22 sections
Benazepril Hydrochloride and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0185-0325	TABLET, FILM COATED	10 mg	ORAL	ANDA	22 sections
Benazepril Hydrochloride and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0185-0325	TABLET, FILM COATED	10 mg	ORAL	ANDA	22 sections
benazepril hydrochloride and hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0574-0227	TABLET	10 mg	ORAL	NDA authorized generic	23 sections
benazepril hydrochloride and hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0574-0228	TABLET	20 mg	ORAL	NDA authorized generic	23 sections
benazepril hydrochloride and hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0574-0229	TABLET	20 mg	ORAL	NDA authorized generic	23 sections
Benazepril Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10544-554	TABLET	20 mg	ORAL	ANDA	13 sections
Benazepril Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10544-561	TABLET, FILM COATED	40 mg	ORAL	ANDA	13 sections
Benazepril Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10544-566	TABLET	10 mg	ORAL	ANDA	13 sections
BENAZEPRIL	HUMAN PRESCRIPTION DRUG LABEL	1	16590-259	TABLET	20 mg	ORAL	ANDA	13 sections
Benazepril Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16590-280	TABLET	10 mg	ORAL	ANDA	12 sections
Benazepril Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	21695-327	TABLET, FILM COATED	20 mg	ORAL	ANDA	19 sections
Benazepril Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	21695-612	TABLET, FILM COATED	5 mg	ORAL	ANDA	19 sections
Amlobenz	HUMAN PRESCRIPTION DRUG LABEL	2	21695-866	CAPSULE	10 mg	ORAL	ANDA	27 sections
Benazepril Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	21695-877	TABLET, FILM COATED	40 mg	ORAL	ANDA	19 sections
Amlobenz	HUMAN PRESCRIPTION DRUG LABEL	2	21695-916	CAPSULE	20 mg	ORAL	ANDA	27 sections
Lotensin	HUMAN PRESCRIPTION DRUG LABEL	1	30698-448	TABLET	10 mg	ORAL	NDA	26 sections